Nosocomial Infections During Extracorporeal Membrane Oxygenation in Pediatric Patients: A Multicenter Retrospective Study

Chunle Wang 1, Shuanglei Li 2, Feng Wang 3, Jinfu Yang 4, Wei Yan 1, Xue Gao 1, Zhiqiang Wen 1 and Yaoyao Xiong 1*

1 Extracorporeal Life Support Center of Cardiovascular Surgery, The Second Xiangya Hospital of Central South University, Central South University, Changsha, China, 2 Cardiovascular Surgery Department, The Sixth Medical Center of People’s Liberation Army of China (PLA) General Hospital, Beijing, China, 3 Department of Pediatric ICU, Affiliated Children’s Hospital of Zhengzhou University, Zhengzhou, China, 4 Cardiovascular Surgery, The Second Xiangya Hospital of Central South University, Central South University, Changsha, China

Objective: Extracorporeal membrane oxygenation (ECMO) is increasingly used in critically ill patients with respiratory and/or cardiac failure. This study aimed to investigate the epidemiology and risk factors of nosocomial infection (NI) in pediatric patients who underwent ECMO for respiratory and/or circulatory failure.

Methods: Medical records for patients that were administered underwent ECMO support at Xiangya Second Hospital of Central South University, The Sixth Medical Center of PLA General Hospital, and Children’s Hospital Affiliation of Zhengzhou University, from September 2012 to December 2019 were retrospectively reviewed. Clinical data of the patients who developed NI were collected and analyzed. Univariate and multivariate logistic regressions were performed to identify the independent predictive factors of NI during ECMO.

Results: A total of 54 first episodes of NI were identified in the 190 patients on ECMO, including 32 cases of respiratory tract infections, 20 cases of bloodstream infections, and 2 cases of surgical site wound infections. Gram-negative pathogens were the dominant pathogens isolated, accounting for 92.6% of the NI. The incidence of ECMO-related NI was 47.6 cases per 1,000 ECMO days. In the univariate logistic regression, ECMO mode, ECMO duration, ICU duration, and peritoneal dialysis were associated with the development of NI in patients with ECMO support. However, in the multivariate analysis, only ECMO duration (OR = 2.46, 95% CI: 1.10, 5.51; P = 0.029), ICU duration (OR = 1.35, 95% CI: 1.05, 1.59; P = 0.017) and peritoneal dialysis (OR = 2.69, 95% CI: 1.08, 5.73; P = 0.031) were the independent predictive factors for NI during ECMO support.

Conclusion: This study identified the significant correlation between ECMO-related NI and ECMO duration, ICU duration, and peritoneal dialysis. Appropriate preventive measures are needed for hospitals to reduce the incidence of ECMO in pediatric patients.

Keywords: extracorporeal membrane oxygenation, children, nosocomial infection, risk factors, ECMO
INTRODUCTION

Extracorporeal membrane oxygenation (ECMO) is an extracorporeal life support (ECLS) strategy for critically ill children with reversible cardiac failure and/or pulmonary failure (1). ECMO support is required by roughly 1% of patients undergoing cardiac surgery as a means of supporting the life circulation (2, 3). During ECMO, blood is drained, diverted to an artificial lung, and then, returned to the patients, which provides respiratory and hemodynamic support (4). However, the cannulation of large blood vessels breaches the barrier protection of patients and provides an easy entry point for pathogens. ECMO is associated with numerous potentially life-threatening complications, such as bleeding, infection, thrombosis, and stroke (5–7). ECMO secondary infections may affect about 31% of patients (8), which not only increase patients’ suffering but also result in death (9). Although some of the complications, such as thrombosis and hemorrhage, have been reduced with the improved technology, nosocomial infections (NIs) present multiple challenges to effective diagnosis and management.

It has only been recently that the NI during ECMO has received attention (6). Since the influenza A (H1N1) pandemic in 2009, especially the new coronavirus pneumonia (COVID-19) global pandemic in 2019, ECMO has been adopted by many hospitals around the world (10–13). A great number of studies have focused on this issue. However, these studies reported different rates and risk factors of NI during ECMO (14–16). In adult patients, NIs are commonly seen in those who have predisposing factors such as patients’ comorbidities, and other life-support procedures (e.g., invasive mechanical ventilation [IMV], renal replacement therapies [RRT]). However, for pediatric populations, the study on NIs acquired during ECMO remains scarce. Thus, we performed this study to investigate the epidemiology and risk factors of NIs in the children population who underwent ECMO for respiratory and/or circulatory failure.

MATERIALS AND METHODS

Study Design and Setting

This study was conducted in compliance with Strengthening the Reporting of Observational Studies in Epidemiology (STORBE) Statement: guidelines for reporting observational studies (17) (Supplementary Material). This retrospective study was performed at Xiangya Second Hospital of Central South University, The Sixth Medical Center of PLA General Hospital, and Children’s Hospital Affiliation of Zhengzhou University, using data collected from organizations’ ECMO database from September 2012 to December 2019. The inclusion criteria were: (1) patients treated with ECMO using a circuit containing a membrane oxygenator and pump, (2) patients who removed a catheter from ECMO treatment within the past 48 h, and (3) patients under 18 years old. Exclusion criteria were: (1) patients who collected data during previous data collection, (2) patients with ECMO extubation > 48 h, and (3) patients with extracorporeal support excluding membrane oxygenators and/or pumps. The study was approved by the Institutional Ethical Committee of the Second Xiangya Hospital of Central South University in China (No. 2020-011).

The clinical data were collected: gender, age, weight, diagnosis at admission (acute respiratory distress syndrome, congenital heart disease, septic shock, pulmonary hypertension, myocarditis, and other diseases), mode of ECMO support (venovenous or venaarterial), mode of cannulation (peripheral or central), renal replacement therapy (CRRT or peritoneal dialysis), transferred from the peripheral hospital (yes or no), extracorporeal cardiopulmonary resuscitation (ECPR: yes or no), ECMO duration (days), hospital duration (days), invasive mechanical ventilation (IMV) duration (days) and intensive care unit (ICU) duration (days).

The criteria of diagnosis at admission were as follows: 1. acute respiratory distress syndrome: a. Identify the acute dyspnea within 1 week; b. Chest X-ray plain film/chest CT showed double lung infiltration shadow; c. Respiratory failure cannot be completely explained by cardiac failure and fluid overload; d. Hypoxemia; 2. congenital heart disease: a. The history of pregnancy: the first 3 months of the pregnant woman had a viral infection, radiation exposure, history of medication, history of diabetes, malnutrition, and environmental and genetic factors; b. Common symptoms: shortness of breath, cyanosis, rapid heart rate (up to 180 beats/min), pause during feeding due to dyspnea, and asthma; c. Development of infant: Infants with congenital heart disease often suffer from malnutrition, a thin body, and growth retardation; and d. Ultrasonography: quantitative measurement of each chamber size and blood vessel in the heart to diagnose the anatomical abnormalities and severity of congenital heart disease. 3. Septic shock: a. under ultrasound or imaging examination, there will be obvious infection focus and systemic infection; b. the decline of blood perfusion leads to organ dysfunction; c. blood pressure drops below 80 / 50 mmHg; d. blood samples were taken to detect the growth of related pathogenic bacteria in blood culture. Pulmonary hypertension: under resting status, the mean pulmonary artery pressure measured by the right cardiac catheter is > or equal to 25 mmHg. Myocarditis: a. Cardiac insufficiency, cardiogenic shock, or cardio cerebral syndrome. b. Cardiac enlargement (X-ray, echocardiography). c. Related ECG changes. d. C-MB was elevated, or cardiac cadherin was positive.

Among the patients, all of them received blood routine examinations and patients with respiratory symptoms received X-ray tests. The diagnosis of NI referred to the diagnostic criteria of the Centers for Disease Control and Prevention/National Nosocomial Infections Surveillance system (18). The ECMO-related NI was defined as a case that had confirmed organisms from one or more blood, respiratory, surgical site wound, or urinary cultures during the initiation of ECMO to 24 h after ECMO weaning (19). In case of suspected infection, the responsible doctor will require routine microbiological examinations (tracheal aspirates, blood cultures, and urine) without E. coli culture. The case was examined by an infectious disease expert and an anesthesiologist to determine if there was a real clinical co-infection. The sites selected for blood
sampling were swabbed with 70% alcohol. Five to 10 milliliters were collected in bactec bottles, transported to the laboratory, and placed in bactec 9,120 instruments. The positive bottles were dyed in Gram and subcultured and tested for sensitivity by the microbiologist. Endotracheal aspirates were obtained by sucking the endotracheal tube or tracheostomy tubes using a sterile suction catheter and the tip cut with a sterile surgical blade, placed in a sterile container, and sent to the laboratory. The purulent part of the vacuum cleaner was used to inoculate MacConkey blood dishes, chocolate, and agar by the lab technician. Chocolate and blood plates were incubated in carbon dioxide at 35–37°C and MacConkey in ambient air for 24 h. Positive cultures that had isolated and sensitive cultures were identified. Medium flow urine or from a sampling port to an internal catheter using an aseptic technique was collected in a sterile container. Samples were used to inoculate MacConkey blood agar and agar, which was incubated at 35–37°C for 18–24 h. Positive cultures were stained with Gram and subcultured and tested for sensitivity. Pus swabs or wounds from ulcers and septic wounds were removed. In laboratory blood, MacConkey and chocolate agar were inoculated, incubated, and treated as mentioned above. All positive microbial cultures obtained from the beginning of ECMO support until 48 h after decannulation were independently evaluated based on available clinical, laboratory, and radiographic data. Accordingly, the following NIs were diagnosed: ventilator-associated pneumonia (VAP), bloodstream infection (BSI, including catheter-related bloodstream infections), and surgical site wound infections. Surgical site wound infections were diagnosed when all the following were present: (1) local erythema and purulent drainage; and (2) cultures of the purulent drainage positive for microorganisms other than common skin contaminants. Only the first NI episode was included in the analysis. The patients were divided into the NI group and non-NI group according to the NI condition.

The diagnosis criteria of VAP were as follows: First, onset after using a ventilator for 48 h; Second, compared with chest X-ray before mechanical ventilation, there was infiltration shadow in the lung or showed new inflammatory lesions; Third, signs of pulmonary consolidation and/or wet rales could be heard in pulmonary auscultation, and one of the following conditions was met: a. blood cells > 10.0*10⁹ / L or < 4*10⁹ / L, with or without nuclear metastasis; b. Fever, body temperature > 37.5°C, a large number of purulent secretions in the respiratory tract; and c. New pathogenic bacteria were isolated from bronchial secretions after onset. The diagnosis criteria of BSI were: First, a recognized pathogen from cultured blood, and the organism cultured was not related to an infection at another site. Organisms considered common skin contaminants were not included in the definition of a recognized pathogen. Second, a fever (>38°C), chills, or hypotension if the patient is > 1 year of age; b. fever (>38°C core) hypothermia (< 36°C core), apnea, or bradycardia if the patient is 1 year of age.

Cannulation of ECMO was performed in a sterile fashion with complex iodine painting. The selection of cannulation model, size, and approach site was determined by the surgeon according to the patient's body weight, height, and vessel size. The management protocol for ECMO follows the Extracorporeal Life Support Organization (ELSO) guidelines.

### Statistical Analysis

Statistical analysis was performed using SPSS 18.0 for Windows (SPSS Chicago, IL, USA). The characteristics of patients in NI and non-NI groups were compared. Continuous variables were expressed as mean ± SD, and a non-parametric test (Mann-Whitney U-test) was used to test the statistical significance. Categorical variables were analyzed using Fisher’s exact test. Univariate and multivariate analyses were performed to identify the independent predictive factors of NI during ECMO. Candidate factors for the multivariable analysis were chosen based on previous findings of univariate analysis and possible biological association (20–23). The odds ratio (OR) was calculated with corresponding 95% confidence intervals (CIs). A receiver operating characteristic (ROC) curve was used to determine the area under the curve (AUC) and the cut-off values of ECMO duration for predicting NI. A two-tailed P-value < 0.05 was considered statistically significant.

### RESULTS

#### Patient Characteristics, and Course and Outcome of ECMO

According to the inclusion and exclusion criteria, we excluded 345 patients, and 190 patients were selected, in which no one had positive cultures before ECMO (Figure 1). The characteristics of 136 patients without NI and 54 patients with NI are shown in Table 1. During the study, 78 neonates (0–28 days) and 112 pediatric patients (28 days–17 years) received ECMO support. The incidence of ECMO-related NI was 47.6 cases per 1,000 ECMO days. About 65% of nosocomial infections occurred within 12 days and 20% within 6 days. The mean delay of onset was 14.5 ± 10.8 days.

Before diagnosed as NI, there were 89 patients with infections received antibiotics among 190 patients included. All the patients with NI received antibiotics, and the standard therapy is as follows: the treatment of participants included in this time must ensure that most Gram-negative bacteria are covered, and the combination treatment of anti-pseudomonal penicillin plus an aminoglycoside, or an antipseudomonal cephalosporin, plus an aminoglycoside is used. If there are Gram-positive bacteria, we add glycopeptides.

There were no significant differences in sex, diagnosis at admission, transferred from the peripheral hospital, antibiotics use, cannulation, ECPR, CRRT, and peritoneal dialysis between the two groups. In the non-NI group, 69 (50.7%) neonates received ECMO support, which was > that in the NI group (n = 9, 16.7%). Acute respiratory distress syndrome and congenital heart disease were the principal diagnoses at the time of admission, which made
up 39.5 and 34.2%, respectively. The ECMO support modes differed significantly between the two groups ($P = 0.02$), with 132 (97.1%) and 47 (87.0%) patients, using V-A ECMO in non-NI and NI groups, respectively. CRRT was used in only 5.8% of patients, and peritoneal dialysis was in 20.5% of patients.

The ECMO duration, IMV duration, ICU duration, and hospital duration were the most significant differences between the two groups. The average ECMO support duration was significantly shorter in the non-NI group ($4 \pm 4.06$ days) than that in the NI group ($5.26 \pm 6.70$ days). The average IMV duration in the non-NI group was $9 \pm 7.93$ days and $17 \pm 15.25$ days in the NI group. The average duration of ICU stay was significantly lower in patients without NI ($13 \pm 14.75$ days) than in patients with NI ($20 \pm 16$ days). Similarly, the hospital duration was significantly shorter in patients without NI ($20 \pm 24.75$ days) than in patients with NI ($31 \pm 29.25$ days).

One hundred and fifteen patients underwent ECMO support weaning with an ECMO survival rate of 60.52%. The Non-NI group survival rate (59.56%) was lower than that of NI group (62.96%), however, this difference was not significant ($P = 0.665$). The overall survival rate was 48.42%, with 48.53% in the non-NI group, and 48.15% in the NI group (Table 1).

### Microorganisms of First Episode Nosocomial Infection

The microorganism distributions of the first episode NI are presented in Table 2. There are 75 episodes in 54 patients, of which 21 patients had another episode of NI. The NI types included 32 respiratory tract infections, 36 BSI, and 7 surgical site wound infections. A total of 90 strains of pathogens were isolated, among which gram-negative pathogens were the dominant (75 strains, 83.3%), mainly including *Acinetobacter baumannii* (31 strains), *Klebsiella pneumonia* (17 strains), *Pseudomonas aeruginosa* (8 strains), *Stenotrophomonas maltophilia* (6 strains), *Pseudomonas paucimobilis* (2 strains), *Burkholderia cepacia* (3 strains), *Burkholderia pickettii* (1 strain), followed by fungal (5 strains, 6.6%), and gram-positive pathogens (2 strains, 2.6%).
**TABLE 1 |** The characteristics of patients with and without nosocomial infections during ECMO.

| Factors                              | All patients | Non-infection | Infection | χ²/Z     | P-value |
|--------------------------------------|--------------|---------------|-----------|----------|---------|
| No. of patients                      | 190          | 136           | 54        |          |         |
| **Age**                              |              |               |           | 18.539   | 0.000   |
| N (0–28days)                         | 78 (41.1%)   | 69 (50.7%)    | 9 (16.7%) |          |         |
| P (28 days – 17 years)               | 112 (58.9%)  | 67 (49.3%)    | 45 (83.3%)|          |         |
| **Gender**                           |              |               |           | 1.666    | 0.225   |
| Male                                 | 130 (68.4%)  | 97 (71.3%)    | 33 (61.1%)|          |         |
| Female                               | 60 (31.6%)   | 39 (28.7%)    | 21 (38.9%)|          |         |
| **Weight (Kg)**                      |              |               |           | 4.016    | 0.000   |
| Transferred from peripheral hospital |              |               |           |          |         |
| Yes                                  | 45 (23.7%)   | 30 (22.1%)    | 15 (27.8%)|          |         |
| No                                   | 145 (76.3%)  | 106 (77.9%)   | 39 (72.2%)|          |         |
| **Diagnosis at admission**           |              |               |           | 9.028    | 0.139   |
| Acute respiratory distress syndrome  | 75 (39.5%)   | 52 (38.2%)    | 23 (42.6%)|          |         |
| Congenital heart disease             | 65 (34.2%)   | 43 (31.6%)    | 22 (40.7%)|          |         |
| Septic shock                         | 7 (3.7%)     | 5 (3.7%)      | 2 (3.7%)  |          |         |
| Pulmonary hypertension               | 15 (7.9%)    | 14 (10.3%)    | 1 (1.9%)  |          |         |
| Myocarditis                          | 23 (12.1%)   | 17 (12.5%)    | 6 (11.1%) |          |         |
| Others                               | 5 (2.6%)     | 5 (3.7%)      | 0         |          |         |
| **Antibiotics use**                  |              |               |           | 0.223    | 0.018   |
| BLA                                  | 38           | 33            | 5         |          |         |
| PA                                   | 13           | 6             | 7         |          |         |
| BLA + PA                             | 133          | 94            | 39        |          |         |
| Others                               | 6            | 3             | 3         |          |         |
| **ECMO support mode**                |              |               |           | 5.399    | 0.02    |
| V-V ECMO                             | 11 (5.8%)    | 4 (2.9%)      | 7 (13.0%) |          |         |
| V-A ECMO                             | 179 (94.2%)  | 132 (97.1%)   | 47 (87.0%)|          |         |
| **Cannulation**                      |              |               |           | 1.619    | 0.209   |
| Peripheral cannulation               | 139 (73.2%)  | 100 (75.7%)   | 36 (66.7%)|          |         |
| Central cannulation                  | 51 (26.8%)   | 33 (24.3%)    | 18 (33.3%)|          |         |
| **CRRT**                             |              |               |           | 0.895    | 0.344   |
| Yes                                  | 11 (5.8%)    | 6 (4.4%)      | 5 (9.3%)  |          |         |
| NO                                   | 179 (94.2%)  | 130 (95.6%)   | 49 (90.7%)|          |         |
| **Peritoneal dialysis**              |              |               |           | 1.348    | 0.319   |
| YES                                  | 39 (20.5%)   | 25 (18.4%)    | 14 (28.6%)|          |         |
| NO                                   | 151 (79.5%)  | 111 (81.6%)   | 40 (71.4%)|          |         |
| **ECPR**                             |              |               |           | 0.779    | 0.444   |
| YES                                  | 20 (10.5%)   | 16 (11.8%)    | 4 (7.4%)  |          |         |
| NO                                   | 170 (89.5%)  | 120 (88.2%)   | 50 (92.6%)|          |         |
| ECMO duration (d)                    | 4.61 ± 4.12  | 4 ± 4.06      | 5.26 ± 6.70|      −3.260| 0.001   |
| IMV duration (d)                     | 11 ± 12      | 9 ± 7.93      | 17 ± 15.25|      −4.424| 0.001   |
| ICU duration (d)                     | 15 ± 17      | 13 ± 14.75    | 20 ± 16   |      −3.670| 0.000   |
| Hospital duration (d)                | 24 ± 26.25   | 20 ± 24.75    | 31 ± 29.25|      −3.466| 0.001   |

ECMO, Extracorporeal membrane oxygenation; BLA, Beta-lactam antibiotics; PA, Polypeptide antibiotics; CRRT, continuous renal replacement therapy; ECPR, Extracorporeal cardiopulmonary resuscitation; IMV, Invasive mechanical ventilation; ICU, Intensive care unit.

**Established ROC Curve**

The ROC curve was performed to assess the ability of ECMO duration to predict NI. The discriminating ability and cut-off of the ECMO duration were as follows: AUC (95%CI: 0.652, 0.735) (Figure 2), and a cut-off value of 3.94 days (Table 3). A significant difference in the discriminative power was observed (P = 0.001).

**Multivariate Analysis of Risk Factors for Nosocomial Infection**

It can be seen from Table 1 that the age, weight, ECMO support mode, ECMO duration, IMV duration, ICU duration, and hospital duration differed significantly between the two groups. In the univariate logistic regression, ECMO mode, ECMO duration, ICU duration, and peritoneal dialysis were
TABLE 2 | Distribution of the Microorganisms of First Nosocomial Infection.

| Gram staining | Microorganism         | Respiratory tract infection (n, %) | Blood stream infection (n, %) | Surgical site wound infection (n, %) | Overall (n, %) |
|---------------|-----------------------|-----------------------------------|------------------------------|-------------------------------------|----------------|
| G-negative bacteria | Acinetobacter baumannii | 18 (24)                           | 13 (17.33)                   | 31 (41.33)                          | 68 (90.7)      |
|                | Klebsiella pneumoniae | 7 (9.33)                           | 7 (9.33)                     | 17 (22.6)                           | 42 (56.6)      |
|                | Pseudomonas aeruginosa| 6 (8)                              | 2 (2.67)                     | 8 (10.6)                            | 10 (13.3)      |
|                | Stenotrophomonas maltophilia | 3 (4)                     | 2 (2.67)                     | 6 (8)                               | 12 (16)        |
|                | Pseudomonas paucimobilis | 2 (2.67)                         | 1 (1.33)                     | 3 (4)                               | 6 (8)          |
|                | Burkholderia cepacia | 2 (2.67)                           | 2 (2.67)                     | 1 (1.3)                             | 5 (6.6)        |
|                | Burkholderia picketti | 1 (1.33)                           | 1 (1.3)                      | 1 (1.3)                             | 3 (4)          |
| G-positive bacterial | Staphylococcus epidermidis | 2 (2.67)                       | 2 (2.67)                     | 2 (2.6)                             | 6 (8)          |
| Fungal | Candida spp | 1 (1.33)                           | 4 (5.33)                     | 5 (6.6)                             | 11 (14.7)      |
|                | Candida parapsilosis | 2 (2.67)                           | 2 (2.67)                     | 2 (2.6)                             | 6 (8)          |
|                | Candida lusitaniae | 1 (1.33)                           | 2 (2.67)                     | 3 (4)                               | 6 (8)          |

TABLE 3 | The specific results of ROC Curve.

| Variables             | Cut-off value | AUC (95%CI) | Youden's index | P     |
|-----------------------|---------------|-------------|----------------|-------|
| ECMO duration (d)     | 3.94          | 0.652 (0.568–0.735) | 0.245          | 0.001 |

associated with the development of NI in patients with ECMO support (Table 4). However, in the multivariate analysis, only ECMO duration (OR = 2.46, 95%CI: 1.10, 5.51; P = 0.029), ICU duration (OR = 1.35, 95%CI: 1.05, 1.59; P = 0.017), and peritoneal dialysis (OR = 2.69, 95%CI: 1.08, 5.73; P = 0.031) were the independent predictive factors for NI during ECMO support. Moreover, subgroup logistic analyses based on infection types were conducted. In respiratory tract infection, univariate analysis showed that ECMO support mode (OR = 1.68, 95%CI: 1.41–4.14), ECMO duration (OR = 1.32, 95%CI: 1.16–1.56), and IMV duration (OR = 1.04, 95%CI: 1–1.08) had a relationship with NI. Multivariate analysis showed only ECMO duration had an association with NI (OR = 1.38, 95%CI: 1.17–1.73). Univariate analysis for bloodstream infection showed weight (OR = 1.05, 95%CI: 1.01–1.09), peritoneal dialysis (OR = 1.33, 95%CI: 0.68–10.98) and hospital duration (OR = 1.03, 95%CI: 1.01–1.06) were significant risk factors for NI. Multivariate analysis also showed the same three significant risk factors, including weight (OR = 1.1, 95%CI: 1.04–1.18), peritoneal dialysis (OR = 2.9, 95%CI: 1.12–5.87), and hospital duration (OR = 1.03, 95%CI: 1.01–1.07). For surgical site wound infection, we did not find significant risk factors which might be attributed to the limited sample size.

DISCUSSION

In this study, we retrospectively analyzed the incidence and risk factors of NI among a large number of pediatric patients receiving ECMO for refractory respiratory or cardiac failure. Our results showed that 28% of patients developed at least one episode of NI during ECMO, which was consistent with the previous results of 20–45% for pediatric and adults patients (19–21). The incidence of NI in this study was 47.6 cases per 1,000 ECMO days, which was in accordance with the previously reported values of between 10 and 116.2 per 1,000 ECMO days (19–21, 23). The prolonged ECMO duration, ICU duration, and peritoneal dialysis were independent factors associated with the development of NI during ECMO.

To the best of our knowledge, this was the first study to investigate the epidemiology and risk factors of NIs in pediatric population who underwent ECMO for respiratory and/or circulatory failure in China. In the present study, we found that gram-negative pathogens were the dominant causative pathogens of respiratory tract infections and BIS during ECMO cannulation, which accounted for 92.6% of nosocomial pathogens. This result was higher than the value of 78% reported by Hsu et al. (25) in adult patients. However, previous studies
showed that gram-positive cocci, especially coagulase-negative staphylococci, were the most frequent pathogen of bloodstream infection during ECMO (19, 21). Hsu et al. stated that the possible reason for the difference between theirs and previous studies was the early administration of glycopeptides and selection of gram-negative pathogens (25).

A variety of studies have assessed the risk factors for developing NI in patients who underwent ECMO. These factors included prolonged duration of ECMO (20–22), venoarterial ECMO (14) and central cannulation (26). In this study, we found that the prolonged duration of ECMO support was an independent risk factor for NI in patients who underwent ECMO. Our result was confirmed by the previous studies (14, 25). Bizzarro et al. conducted a retrospective study on 20,741 patients and found that longer ECMO support was significantly associated with the NI irrespective of age. Patients who underwent ECMO for less than 1 week had a 6.1% risk of NI, as compared with 15.7% of those receiving ECMO for between 8 and 14 days, and 30.3% for those receiving ECMO for more than 2 weeks (P < 0.001) (14). For adult patients, the risk of NI was 12.8% in those with ECMO for < a week, compared to 51.6% in those with ECMO for more than 2 weeks (P < 0.001) (14). Hsu et al. also found that the NI rate increased three-fold when the duration of ECMO exceed more than 10 days (5.7 vs. 19.2%) (25). The ICU duration was also found to be an independent risk factor for NI in the multivariate analysis, however, its effect was not as strong as the ECMO duration (OR = 1.35 vs. 2.46). Furthermore, concerning respiratory tract infection, ECMO support mode and duration along with IMV duration need attention. In BSI, weight, peritoneal dialysis, and hospital duration might be risk factors for NI. These findings were partly consistent with previous studies (24, 25).

The clinical diagnosis of NI in ECMO patients is challenging because observable symptoms/signs of the patients may not be present. Fever is often non-apparent since body temperature is controlled by an ECMO heat exchanger and patients invariably have signs of the systemic inflammatory response, possibly triggered by ECMO itself (21, 27). For this reason, we only analyzed patients with microbiologically confirmed infections. Concerning the causative microorganisms, previous research showed that Staphylococcus aureus and other Staphylococcus species (38%) were the most common pathogens causing BSI,
TABLE 4 | Univariate analysis and multivariate analysis of risk factors for Nosocomial infections during ECMO.

| Factors                     | Univariate analysis | Multivariate analysis |
|-----------------------------|---------------------|-----------------------|
|                             | OR      | 95%CI      | P-value | OR      | 95%CI      | P-value |
| Age                         | 0.85    | 0.72–1.16  | 0.053   | 0.88    | 0.73–1.08  | 0.076   |
| Weight                      | 0.38    | 0.07–1.84  | 0.241   | 0.39    | 0.10–1.13  | 0.082   |
| Peritoneal dialysis         | 2.72    | 1.15–6.43  | 0.022*  | 2.69    | 1.08–6.73  | 0.031*  |
| ECMO support mode           | 1.84    | 1.43–2.45  | 0.001*  | 1.71    | 0.86–3.39  | 0.554   |
| ECMO duration (d)           | 2.23    | 1.08–6.38  | 0.036*  | 2.46    | 1.10–6.51  | 0.029*  |
| IMV duration (d)            | 1.49    | 0.82–1.86  | 0.452   | 1.47    | 0.98–1.64  | 0.063   |
| ICU duration (d)            | 1.33    | 1.04–1.66  | 0.024*  | 1.35    | 1.05–1.59  | 0.017*  |
| Hospital duration (d)       | 1.08    | 0.91–1.43  | 0.217   | 1.10    | 0.92–1.54  | 0.768   |

Respiratory tract infection

| Age                         | 0.95    | 0.85–1.05  | 0.347   | 1       | 0.84–1.14  | 0.982   |
| Weight                      | 0.45    | 0.21–1.06  | 0.361   | 0.49    | 0.38–0.55  | 0.751   |
| Peritoneal dialysis         | 0.89    | 0.25–2.84  | 0.849   | 2.49    | 0.5–12.5   | 0.257   |
| ECMO support mode           | 1.68    | 1.41–4.14  | 0.026*  | 2.45    | 0.28–6.33  | 0.355   |
| ECMO duration (d)           | 1.32    | 1.16–1.56  | 0.001*  | 1.38    | 1.17–1.73  | 0.001*  |
| IMV duration (d)            | 1.04    | 1–1.08     | 0.032*  | 0.98    | 0.91–1.06  | 0.602   |
| ICU duration (d)            | 1.02    | 0.99–1.06  | 0.125   | 0.97    | 0.87–1.06  | 0.499   |
| Hospital duration (d)       | 0.02    | 1–1.05     | 0.051   | 1.05    | 1–1.14     | 0.178   |

Blood stream infection

| Age                         | 1.07    | 0.98–1.17  | 0.112   | 0.97    | 0.84–1.08  | 0.575   |
| Weight                      | 1.05    | 1.01–1.09  | 0.017*  | 1.1     | 1.04–1.18  | 0.001*  |
| Peritoneal dialysis         | 1.33    | 0.68–10.98 | 0.048*  | 2.9     | 1.12–5.87  | 0.005*  |
| ECMO support mode           | 1.98    | 1.55–3.21  | 0.993   | 0       | 0.35–4.55  | 0.993   |
| ECMO duration (d)           | 0.97    | 0.8–1.13   | 0.701   | 0.83    | 0.63–1.04  | 0.133   |
| IMV duration (d)            | 1.04    | 0.95–1.12  | 0.406   | 1.17    | 0.98–1.42  | 0.087   |
| ICU duration (d)            | 1.03    | 0.97–1.1   | 0.356   | 0.93    | 0.8–1.06   | 0.287   |
| Hospital duration (d)       | 1.03    | 1.01–1.08  | 0.016*  | 1.03    | 1.01–1.07  | 0.027*  |

Surgical site wound infection

| Age                         | 0.91    | 0.74–1.06  | 0.271   | 0.99    | 0.74–1.16  | 0.603   |
| Weight                      | 0.97    | 0.89–1.06  | 0.497   | 0.51    | 0.87–1.69  | 0.511   |
| Peritoneal dialysis         | 0.94    | 0.11–9.1   | 0.952   | 5.55    | 0.06–15.83 | 0.561   |
| ECMO support mode           | 2.52    | 1.98–4.42  | 0.996   | 0.85    | 0.25–1.85  | 0.997   |
| ECMO duration (d)           | 0.98    | 0.85–1.14  | 0.789   | 1       | 0.81–1.24  | 0.985   |
| IMV duration (d)            | 0.98    | 0.93–1.02  | 0.422   | 0.77    | 0.39–1.04  | 0.314   |
| ICU duration (d)            | 0.99    | 0.95–1.03  | 0.562   | 1.32    | 0.96–2.74  | 0.316   |
| Hospital duration (d)       | 0.99    | 0.96–1.01  | 0.271   | 0.97    | 0.87–1     | 0.301   |

*P-value < 0.05.

followed by *Escherichia coli* (24%), in critically ill patients without ECMO support (28, 29). However, the balance was shifting from multi-resistant *staphylococci* to highly resistant classes of *A. baumannii* and *P. aeruginosa*. In our study, *A. baumannii* was the most common pathogen in both blood and the respiratory tract, which would be a common pathogen in the ICU environment. We also found 3 cases of developed fungal infections, which accounted for 5.6% of nosocomial pathogens. Similarly, Giacomo et al. (30) reported 17% of the fungal infection during ECMO support. The shift from G-positive to G-negative bacteria can be possibly explained by the increased antimicrobial exposure, intestinal microbiota selection during the hospital stay (31), and the gut mucosal barrier impairment.

There were several potential limitations in this study. First, this study was a multicenter retrospective cohort study, and as such, it can only suggest associations of risk factors without inferring reasons for NI (32). Second, although cases in this study were enrolled, the clinical information of risk factors was collected retrospectively, which might result in a selection bias. Third, the retrospective nature of this cohort study is limited to medical patients only, which precludes the extrapolation of the results to the general population of patients with medical ECMO. Fourth, due to the lack of sufficient data about the patient outcome, we are not able to investigate the prognostic factors of Nis in these patients.
In conclusion, this study investigated the epidemiology and risk factors of NI in pediatric patients who underwent ECMO for respiratory and/or circulatory failure. Risk factors for NI during ECMO included a longer duration of ECMO and ICU and peritoneal dialysis. Given that all the available data are obtained retrospectively, a prospective study focusing on this topic is needed to verify our findings.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Institutional Ethical Committee of the Seventh Medical Center of PLA General Hospital in China. Written informed consent to participate in this study was provided by the participants or their legal guardian/next of kin.

**AUTHOR CONTRIBUTIONS**

ZW and YX attributed to the study design. CW, SL, FW, and JY contributed to data collection. CW, SL, WY, and XG did the data analyses. CW, SL, and YX wrote the manuscript. All authors read and approved the final manuscript.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped.2022.873577/full#supplementary-material

**REFERENCES**

1. Sherwin J, Heath T, Watt K. Pharmacokinetics and dosing of anti-infective drugs in patients on extracorporeal membrane oxygenation: a review of the current literature. Clin Ther. (2016) 38:1976–94. doi: 10.1016/j.clinthera.2016.07.169
2. Smith C, Bellomo R, Raman JS, Matalanis G, Rosalion A, Buckmaster J, et al. An extracorporeal membrane oxygenation-based approach to cardiogenic shock in an older population. Ann Thorac Surg. (2001) 71:1421–7. doi: 10.1016/s0003-4975(00)02504-2
3. Allen S, Holena D, McCunn M, Kohl B, Sarani B. A review of the fundamental principles and evidence base in the use of extracorporeal membrane oxygenation (ECMO) in critically ill adult patients. J Intensive Care Med. (2011) 26:13–26. doi: 10.1177/0885066610384061
4. Buß S, Di Bella S, Scarsavili V, Peri AM, Grasselli G, Alagna L, et al. Infections during extracorporeal membrane oxygenation: epidemiology, risk factors, pathogenesis and prevention. Int J Antimicrob Agents. (2017) 50:9–16. doi: 10.1016/j.ijantimicag.2017.02.025
5. MacLaren G, Combes A, Bartlett RH. Contemporary extracorporeal membrane oxygenation for adult respiratory failure: life support in the new era. Intensive Care Med. (2012) 38:210–20. doi: 10.1007/s00134-011-2439-2
6. Butt W, Heard M, Peek GJ. Clinical management of the extracorporeal membrane oxygenation circuit. Pediatr Crit Care Med. (2013) 14:S13–19. doi: 10.1097/PCC.0b013e31828292dc8
7. Combes A, Leprince P, Luyt CE, Bonnet N, Trouillet JL, Léger P, et al. Outcomes and long-term quality-of-life of patients supported by extracorporeal membrane oxygenation for refractory cardiac shock. Crit Care Med. (2008) 36:1404–11. doi: 10.1097/CCM.0b013e318167cf7d
8. Cheng R, Hachamovitch R, Kittleson M, Patel J, Arabia F, Moriguchi J, et al. Complications of extracorporeal membrane oxygenation for treatment of cardiogenic shock and cardiac arrest: a meta-analysis of 1,866 adult patients. Ann Thorac Surg. (2014) 97:610–6. doi: 10.1016/j.athoracsur.2013.09.008
9. Liu X, Xu Y, Zhang R, Huang Y, He W, Sang L, et al. Survival predictors for severe ards patients treated with extracorporeal membrane oxygenation: a retrospective study in China. PLoS ONE. (2016) 11:e0158061. doi: 10.1371/journal.pone.0158061
10. Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet (London, England). (2009) 374:1351–63. doi: 10.1016/s0140-6736(09)61069-2
11. Davies A, Jones D, Bailey M, Beca J, Bellomo R, Blackwell N. Extracorporeal Membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome. Jama. (2009) 302:1888–95. doi: 10.1001/jama.2009.1355
12. Ma X, Liang M, Ding M, Liu W, Ma J, Zhou X, et al. Extracorporeal membrane oxygenation (ECMO) in critically ill patients with coronavirus disease 2019 (COVID-19) pneumonia and acute respiratory distress syndrome (ARDS). Med Sci Monit. (2020) 26:e925364. doi: 10.2165/959.25364
13. Kowalewski M, Fina D, Slomka A, Raffa GM, Martucci G, Lo Coco V. COVID-19 and ECMO: the interplay between coagulation and inflammation-a narrative review. Critical care (London, England). (2020) 24:205. doi: 10.1186/s13054-020-02925-3
14. Bizzarro MJ, Conrad SA, Kaufman DA, Rycus P. Infections acquired during extracorporeal membrane oxygenation in neonates, children, and adults. Pediatr Crit Care Med. (2011) 12:277–81. doi: 10.1097/PCC.0b013e3181e28894
15. Müller T, Lubnow M, Philipp A, Schneider-Barrantz W, Camboni D, Schmid C, et al. Risk of circuit infection in septic patients on extracorporeal membrane oxygenation: a preliminary study. Artif Organs. (2011) 35:EB48–90. doi: 10.1111/j.1525-1594.2010.01185.x
16. Bowman ME, Rebekya IM, Ross DB, Quinonez LG, Forgie SE. Risk factors for surgical site infection after delayed sternal closure. Am J Infect Control. (2013) 41:464–5. doi: 10.1016/j.ajic.2012.05.022
17. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (London, England). (2007) 370:1453–7. doi: 10.1016/s0140-6736(07)61602-x
18. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. (1988) 16:128–40. doi: 10.1016/0196-6553(88)90033-3
19. Burket JS, Bartlett RH, Vander Hyde K, Chenoweth CE. Nosocomial infections in adult patients undergoing extracorporeal membrane oxygenation. Clin Infect Dis. (1999) 28:828–33. doi: 10.1086/315200
20. O’Neill JM, Schutze GE, Heulitt MJ, Simpson PM, Taylor BJ. Nosocomial infections during extracorporeal membrane oxygenation. Intensive Care Med. (2001) 27:1247–53. doi: 10.1007/s001340101029
21. Steiner CK, Stewart DL, Bond SJ, Hornung CA, McKay VJ. Predictors of surgical site infection after delayed sternal closure. Am J Surg. (2007) 194:127–31. doi: 10.1016/j.amjsurg.2007.02.003
22. Schutze GE, Heulitt MJ. Infections during extracorporeal life support. J Pediatr Surg. (1995) 30:809–12. doi: 10.1016/0022-3468(95)90753-x
23. Coffin SE, Bell LM, Manning M, Polin R. Nosocomial infections in neonates receiving extracorporeal membrane oxygenation. *Infection control and hospital epidemiology*. (1997) 18:93–6. doi: 10.1086/647561

24. Ayyildiz P, Kazar T, Ozturk E, Yildiz O, Ozturk S, Ergul Y, et al. The evaluation of nosocomial infections in pediatric patients with extracorporeal membrane oxygenation support. *Brazilian j cardiovascular surg.* (2017) 32:468–74. doi: 10.21470/1678-9741-2017-0072

25. Hsu MS, Chiu KM, Huang YT, Kao KL, Chu SH, Liao CH. Risk factors for nosocomial infection during extracorporeal membrane oxygenation. *J Hosp Infect.* (2009) 73:210–6. doi: 10.1016/j.jhin.2009.07.016

26. Brown KL, Ridout DA, Shaw M, Dodkins I, Smith LC, O’Callaghan MA. Healthcare-associated infection in pediatric patients on extracorporeal life support: The role of multidisciplinary surveillance. *Pediatr Crit Care Med.* (2006) 7:546–50. doi: 10.1097/01.pcc.0000243748.74264.ce

27. Meyer DM, Jessen ME, Eberhart RC. Neonatal extracorporeal membrane oxygenation complicated by sepsis. extracorporeal life support organization. *Annals thoracic surgery*. (1995) 59:975–80. doi: 10.1016/0003-4975(95)00044-1

28. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH. The prevalence of nosocomial infection in intensive care units in Europe. results of the European prevalence of infection in intensive care (EPIC) study. EPIC international advisory committee. *JAMA*. (1995) 274:639–644

29. Pappas PG, Kauffman CA, Andes D, Benjamint DK, Calandra TF, Edwards JE. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. *Clin Infect Dis.* (2009) 48:503–35. doi: 10.1086/596757

30. Grasselli G, Scaravilli V, Di Bella S, Biffi S, Bombino M, Patroniti N. Nosocomial Infections During Extracorporeal Membrane Oxygenation: Incidence, Etiology, and Impact on Patients’ Outcome. *Crit Care Med.* (2017) 45:1726–33. doi: 10.1097/ccm.0000000000002652

31. Doyle JS, Buisse KL, Thursky KA, Worth LJ, Richards MJ. Epidemiology of infections acquired in intensive care units. *Semin Respir Crit Care Med.* (2011) 32:115–38. doi: 10.1055/s-0031-1275525

32. Keogh RH, Cox DR. *Case-Control Studies*. Cambridge: Cambridge University Press (2014).

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Wang, Li, Wang, Yang, Gao, Wen and Xiong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.